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Background/Aim: Neurofibromatosis type 1 (NF1) is characterized by the occurrence of multisystem tumors. The objective of this study 
was to analyze the demographic and oncological profile of 830 NF1-individuals regarding prevalence, type, and spectrum of malignancy. 
Patients and methods: The medical records of patients diagnosed with NF1 with a median age of 22.1 years (range: 0.8–81.6 years) who 
were followed up for malignancies from 1999 to 2018 were retrospectively reviewed. Results: The prevalence of malignancy occurring 
in patients diagnosed with NF1 was 34.8% (289/830). The most common types of neoplasia encompassed tumors strictly associated 
with NF1, including plexiform neurofibromas (PNF; 200/830; 24.1%) and optic pathway gliomas (91/830; 11%). The prevalence of 
PNFs-transforming to malignant peripheral nerve sheath tumors (MPNST) was 3.5% (7/200). The prevalence of other tumors was 4.8% 
(40/830). One patient was diagnosed with acute myeloid leukemia (AML), thus the risk of hematological malignancies among all patients 
with NF1 was 0.1% (1/830). In the population of patients with malignancies, 43/289 (14.9%) individuals were diagnosed with more than 
one malignancy. Conclusions: The odds ratio (OR) of malignancy in a studied cohort of patients with NF1 was 23 (p < 0.001), while the 
OR of hematological malignancy was 5.1 (p = 0.1) in comparison with the general population.
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Introduction
Neurofibromatosis type 1 (NF1) is one of the most common genetically 
determined disease and is characterized by 5–15% higher risk of 
malignant tumor formation than the general population [1]. The NF1- 
-associated NF1 gene is the tumor suppressor gene. The mutations 
occurring in NF1-patients cause the inactivation of the gene, 
predisposing to certain types of tumors arising from the embryonic 
neural crest [2, 3]. Therefore, there is an association between NF1 
and the following malignancy: gliomas, malignant peripheral nerve 
sheath tumors (MPNSTs), breast cancers, pheochromocytomas, 
rhabdomyosarcomas, gastrointestinal stromal tumors (GIST), 
melanomas and certain hematological malignancies, primarily acute 
myeloid leukemia (AML), and juvenile myelomonocytic leukemia 
(JMML) [4, 5].
The Phacomatosis Center in Bydgoszcz provides health care for 
patients with NF1, both children and adults. The objective of this study 
was to analyze the demographic and clinical profile of NF1-individuals 
regarding incidence, type, and spectrum of malignancy.
Patients and methods
Data collection
The medical records of patients diagnosed with NF1 who were 
followed up in the Phacomatosis Center in the Department of Pediatric 
Hematology and Oncology in Bydgoszcz from 1999 to 2018 were 
analyzed. The diagnosis of NF1 was based on the clinical criteria set by 
the National Institutes of Health (NIH) in patients with at least two of the 
seven following features: ≥6 cafe au lait macules (>0.5 cm in diameter 
before puberty and >1.5 cm in diameter after puberty), axillary and/
or inguinal freckling, ≥2 Lisch nodules (iris hamartomas), ≥2 discrete 
neurofibromas or ≥1 plexiform neurofibroma (PNF), an optic pathway 
glioma (OPG), distinctive bony lesions (i.e., long bone dysplasia), and 
a first-degree relative with NF1 [6]. Medical records of patients were 
reviewed for demographic and occurrence of malignancies. Due to the 
retrospective character of the study, the age of patients was determined 
at the time of analysis. In many cases, there was no information about 
the age associated with the time of diagnosis of malignancy; therefore 
this parameter has not been evaluated.
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Statistical analysis
Baseline parameters were compared between groups using Chi-
squared or Fisher’s exact tests for prevalences. Odds ratio (OR) 
and 95% confidence intervals (95% CI) were calculated for the 
differences in prevalence in comparison with general population. 
Data on the epidemiology of malignancies in Poland in 2015 were 
taken as a reference denominator [7]. Data analysis was carried out 
using SPSS 25 (IBM SPSS Statistics, Version 25.0) and Epi-Info 
(Version 7.2.1.0). Statistical significance was regarded as p < 0.05.
Results
Demographics and oncological profile
A total number of 830 patients diagnosed for NF1 were referred to 
the Phacomatosis Center from 1999 to 2018, including 454 females 
(54.7%) and 376 males (45.3%), with a median age of 22.1 years 
(range: 0.8–81.6 years). The localized cutaneous neurofibromas 
were not included in the analysis. The prevalence of malignancy 
occurring in patients diagnosed for NF1 was 34.8% (289/830). 
Types of malignancies and characteristics of affected patients are 
presented in table I. As expected, tumors strictly associated with 
NF1, such as OPGs and PNFs, were the most common in our study 
group. The prevalence of other than OPGs, PNFs and MPNSTs 
malignancies in NF1-individuals was 4.8% (40/830), and the median 
age of these patients was 28.8 years. The prevalence of malignancies 
required oncological treatment (excluded low-grade OPGs and non-
aggressive PNFs) in analyzed patients was 8.9% (74/830). The 
distribution of these tumors is shown in figure 1. One patient was 
diagnosed with AML; thus, the risk of hematological malignancies 
among all patients with NF1 was 0.1% (1/830). In addition, one 
patient developed severe aplastic anemia at the age of 17 years. 
In the population of patients with malignancies, 43/289 (14.9%) 
individuals were diagnosed for more than one malignancy including 
two patients with three malignancies (Tab. II). The risk of multiple 
Table I. Characteristics of patients with malignancies
Malignancies Number of patients (%)





Management Observation only 184 (22.2) 27.8 M = 91, F = 93
Without progression to MPNST, onco-
logical treatment required
9 (1.1) 32.5 M = 2, F = 7
With progression to MPNST 7 (0.8) 32.4 M = 2, F = 5
OPG
(n = 91; 11%)
Management Observation only 73 (8.8) 18.9 M = 31, F = 42
Oncological treatment required 18 (2.2) 14.7 M = 5, F = 13
Brain tumor, another than OPG 18 (2.2) 26.4 M = 8, F = 10
Sarcoma another than 
MPNST
(n = 8; 1%)
Localization Nasopharynx 1 (0.1) 41.0 M = 0, F = 1
Soft tissue of the gluteal region 1 (0.1) 27.6 M = 0, F = 1
Abdominal cavity 1 (0.1) 57.2 M = 1, F = 0
Testicle 1 (0.1) 6.4 M = 1, F = 0
Vagina 1 (0.1) 2.6 M = 0, F = 1
Collarbone 1 (0.1) 42.3 M = 1, F = 0
Orbital bone 1 (0.1) 8.0 M = 0, F = 1
GIST 1 (0.1) 56.8 M = 0; F = 1
Breast cancer 5 (0.6) 56.8 M = 0, F = 5
Pheochromocytoma 2 (0.2) 55.0 M = 1, F = 1
Adrenal adenocarcinoma 2 (0.2) 30.4 M = 1, F = 1
Medullary thyroid cancer 1 (0.1) 43.9 M = 0, F = 1
Skin melanoma 1 (0.1) 28.0 M = 0. F = 1
Ocular melanoma 1 (0.1) 43.6 M = 1, F = 0
Endometrial cancer 1 (0.1) 54.2 M = 0, F = 1
Liver cancer 1 (0.1) 16.5 M = 1, F = 0
Colorectal cancer 1 (0.1) 56.7 M = 1, F = 0
HEMATOLOGIC MALIGNANCIES
AML 1 (0.1) 7.2 M = 1, F = 0
PNF – plexiform neurofibroma; MPNST – malignant peripheral nerve sheath tumor; OPG – optic pathway glioma; GIST – gastrointestinal stromal tumor; AML – acute myeloid leukemia; 
M – male; F – female
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Fig. 1. The percentage of required oncological treatment different tumor types in NF1-patients 
PNF – plexiform neurofibroma; MPNST – malignant peripheral nerve sheath tumor; OPG – optic pathway glioma; AML – acute myeloid leukemia
Table II. Characteristics of patients with multiple malignancies
Malignancies Number of patients (%) Age at the time of analysis (years) Gender
OPG
PNF
27 (3.3) 26.5 M = 13, F = 14
PNF
Brain cancer (not OPG)








1 (0.1) 56.8 M = 0, F = 1
OPG
Testicular sarcoma
1 (0.1) 6.4 M = 1, F = 0
OPG
Breast cancer
1 (0.1) 45.8 M = 0, F = 1
PNF
Liver cancer
1 (0.1) 16.5 M = 1, F = 0
PNF
Nasopharyngeal sarcoma
1 (0.1) 41.0 M = 0, F = 1
PNF
Colorectal carcinoma
1 (0.1) 56.7 M = 1, F = 0
PNF
Adrenal adenocarcinoma
1 (0.1) 33.3 M = 0, F = 1
Brain tumor (not OPG)
Endometrial cancer
1 (0.1) 54.2 M = 0, F = 1
OPG – optic pathway glioma; PNF – plexiform neurofibroma; GIST – gastrointestinal stromal tumor; M – male; F – female
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malignancies in NF1-patients was 5.2% (43/830); however, the risk 
of multiple malignancies other than OPGs, PNFs, and MPNSTs was 
0.2% (2/830).
Comparison with the general population
With the estimated 0.43% (163,281/37.95 million) incidence of 
malignant diseases in the general Polish population in 2015 and 
estimated overall number of 1 million patients with malignancies, 
the OR of malignancy in the studied group of patients with NF1 was 
123 (95% CI = 107–142, p < 0.001) in comparison with the general 
population. After exclusion from the analysis of patients with benign 
malignancies requiring observation with “watch and wait” strategy 
only (low-grade OPGs and non-aggressive PNFs), the OR of 
malignancy in NF1-individuals was 23 (95% CI = 18–29; p < 0.001) in 
comparison with the general population. With the estimated number 
of 9,855 newly diagnosed patients with leukemia or lymphoma in 
2015 in Poland, the OR of hematological malignancy in NF1 patients 
was 5.1 (95% CI = 0.7–36; p = 0.1) in comparison with the general 
population. A comparison of cancer prevalence between patients 
with NF1 and the general Polish population in particular age groups 
[7] is presented in figure 2.
Discussion
It is known that NF1-patients carry a higher risk of developing soft 
tissue sarcomas, and there is a strong association between NF1 
and MPNST [8, 9]. The lifetime risk of MPNST developing in NF1-in 
-dividuals has been estimated at 8–13%, as compared with 0.001% 
in the general population [10, 11]. In our cohort, the prevalence 
of all PNFs was 24.1% (200/830), while the prevalence of PNFs- 
-transforming to MPNST was 3.5% (7/200). The median age of 
patients with stable PNFs was 27.8 years, so the percentage of 
patients with malignant transformation can be expected to increase 
significantly over the next 10–15 years because the median age 
for NF1-associated MPNST is between 20 and 40 years [12]. In 
addition to MPNST, we observed other soft tissue sarcoma in 
patients, mainly rhabdomyosarcoma (RMS). These tumors had 
various locations, and there were no predispositions for specific age 
groups. The pathogenesis of RMS in NF1 patients appears even 
less clear than for MPNST. In the study on a small group of patients, 
it was observed that RMSs arising in NF1-patients tend to have 
certain particular characteristics: embryonal histotypes, a pelvic or 
genitourinary tract locations, and onset in the first decade of life 
[11]. Other tumors diagnosed in our cohort included bone sarcomas 
(2/830; 0.2%) and GIST (1/830; 0.1%). The prevalence of all 
sarcomas was 1.8% (15/830), including non-MPNST sarcoma with 
a prevalence of 1% (8/830). For comparison, the world incidence 
rate of sarcomas is 5 per 100,000 individuals in the general 
population per year [13].
OPGs affect about 15% of patients with NF1 and usually arise during 
the first decade of life [8, 14]. In our cohort, the prevalence of OPGs was 
11%. OPGs were more common among female patients [60% (55/91) 
vs. 40% (36/91)]. Also more aggressive course of these tumors was 
observed in females. Oncological treatment due to the progression of 
OPGs growth was used in 13 female patients and 5 male individuals. 
The clinical course of NF1-OPGs may be unpredictable, although 
age and sex of patients have been associated with an increased risk 
of clinical progression: female patients are more likely to lose vision 
and require treatment for OPGs than male patients, and girls with 
optic nerve gliomas are 5–10 times more likely to experience visual 
decline than boys. In addition, lesions presenting at the age <2 years 
or after the age of 8–10 years are usually more aggressive than those 
presenting in children between 2 and 8 years [15].
Young patients with NF1 have up to a 500-fold increased risk of 
developing myeloid disorders, especially JMML, which is a rare and 
aggressive form of leukemia, typically diagnosed in early childhood. 
About 15% of patients with JMML are affected by NF1 [5]. Stiller et 
Fig. 2. Comparison of cancer prevalence between patients with NF1 and the general population in particular age groups
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al. (1994) estimated relative risk to be 224 for the development of 
myelomonocytic leukemia (MML) in NF1-patients. The relative risks 
of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma 
(NHL) were also increased with the values of 5.4 and 10, respectively 
[16]. Juvenile xanthogranulomas (JXG) were seen with an increased 
incidence in NF1, and their presence may be associated also with 
an increased risk of JMML [5]. The existence of lymphoid neoplasms 
in NF1-patients, particularly diffuse large B-cell lymphoma (DLBCL), 
has been infrequently reported [5]. In our relatively large cohort, we 
met only one patient with hematologic malignancy (1/830; 0.1%), 
and additionally, one child developed aplastic anemia. None of our 
patients developed JMML.
Somatic mutation of the NF1 gene was reported in 27.7% of all breast 
cancers and has been implicated as potential genomic drivers in the 
development of this carcinoma. Based on a systematic literature 
review, Suarez-Kelly et al. [17] suggested that female NF1-patients 
under  50 years have a fivefold increased risk of breast cancer, 
present with more advanced disease, and may have an increased 
this cancer-related mortality. In our analysis, the risk of breast cancer 
in women with NF1 was 4.3-fold higher than in the general Polish 
population (0.6% vs. 0.14%) [18]. Evans et al. [19] determined the risk 
of contralateral breast cancer and survival in 142 women with NF1 
(median age 46.9 years; range 27.0–84.3 years). The cumulative risk 
for contralateral breast cancer was 26.5% in 20 years. Five and 10-year 
overall survival was 64.9% and 49.8% respectively in his study.
Life expectancy in people with NF1 is reduced by about 15 years in 
comparison with the general population, with malignancy being the 
most common cause of death [5]. Undoubtedly, the data presented 
in figure 2 confirm this claim. NF1-individuals develop malignancies 
earlier when compared to the general population. These patients 
have a high risk of developing various types of cancer, and the 
course of treatment is difficult due to the numerous diseases 
associated with NF1. A more aggressive course of oncological 
disorders or higher drug resistance is frequently observed.
Currently, a coordinated system of care for patients with NF1 is being 
created in Poland with the main centers in Bydgoszcz, Warsaw and 
Gdańsk. This will allow patients to get quick access to diagnostics 
and treatment. This approach in the long-term period should result 
in improved quality of life and overall survival of patients with NF1. 
Vigilant medical care for patients is necessary from an early age. It is 
very important to spread awareness about the diagnosis and course 
of NF1 among physicians of all specialties, with distinction for primary 
care physicians.
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